메뉴 건너뛰기




Volumn 41, Issue 3, 2012, Pages 223-226

Pulmonary events in antiphospholipid syndrome: Influence of antiphospholipid antibody type and levels

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

EID: 84860568925     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.641580     Document Type: Article
Times cited : (15)

References (15)
  • 1
    • 0033834033 scopus 로고    scopus 로고
    • Epidemiology of the antiphospholipid antibody syndrome
    • Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
    • (2000) J. Autoimmun , vol.15 , pp. 145-151
    • Petri, M.1
  • 2
    • 33744987382 scopus 로고    scopus 로고
    • Pulmonary manifestations in antiphospholipid syndrome
    • DOI 10.1016/j.autrev.2006.02.002, PII S1568997206000206
    • Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006;5:344-8. (Pubitemid 43868201)
    • (2006) Autoimmunity Reviews , vol.5 , Issue.5 , pp. 344-348
    • Stojanovich, L.1
  • 5
    • 77951234806 scopus 로고    scopus 로고
    • CAPS registry project group catastrophic antiphospholipid syndrome (CAPS): Update from the 'caps registry
    • Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): Update from the 'CAPS Registry'. Lupus 2010;19:412-18.
    • (2010) Lupus , vol.19 , pp. 412-418
    • Cervera, R.1
  • 8
    • 0012008982 scopus 로고    scopus 로고
    • Reliability of selena, sledai and flare as clinical trial outcome measures
    • Petri M, Buyon J, Skovron ML. Reliability of SELENA, SLEDAI and flare as clinical trial outcome measures. Arthritis Rheum 1998;41:S218.
    • (1998) Arthritis Rheum , vol.41
    • Petri, M.1    Buyon, J.2    Skovron, M.L.3
  • 10
    • 0024427029 scopus 로고
    • Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients
    • Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65. (Pubitemid 19286655)
    • (1989) Medicine , vol.68 , Issue.6 , pp. 353-365
    • Alarcon-Segovia, D.1    Deleze, M.2    Oria, C.V.3    Sanchez-Guerrero, J.4    Gomez-Pacheco, L.5    Cabiedes, J.6    Fernandez, L.7    Ponce De Leon, S.8
  • 12
    • 0023220110 scopus 로고
    • The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level
    • Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987; 106:524-31. (Pubitemid 17095036)
    • (1987) Annals of Internal Medicine , vol.106 , Issue.4 , pp. 524-531
    • Petri, M.1    Rheinschmidt, M.2    Whiting-O'Keefe, Q.3
  • 15
    • 0035377062 scopus 로고    scopus 로고
    • Following 90 patients with antiphospholipid syndrome with antibody levels and correlations with clinical manifestations: Symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population
    • Marai I, Levim Y, Godard G, Shoenfeld Y. Following 90 patients with antiphospholipid syndrome with antibody levels and correlations with clinical manifestations: Symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population. Harefuah 2001;140: 495-500.
    • (2001) Harefuah , vol.140 , pp. 495-500
    • Marai, I.1    Levim, Y.2    Godard, G.3    Shoenfeld, Y.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.